



Leukemia subtypes and biomarkers



References:

1. Alchalby, H. (2010) Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. *Blood* **116**, 3572.
2. Antonioli, E., et al. (2010) Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. *Haematologica* **95**, 1435.
3. Arber, D.A., et al. (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* **127**, 2391.
4. Barbui, T., et al. (2011) Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. *J. Clin. Oncol.* **29**, 761.
5. Bjorn, M.E., et al. (2014) Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. *Leuk. Res. Rep.* **3**, 73.
6. Döhner, H., et al. (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* **129**, 424.
7. Eichhorst, B., et al. (2015) Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**, v78.
8. Girodon, F., et al (2008) Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. *Haematologica* **93**, 1723.
9. Gisslinger, H., et al. (2020) Ropoginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. *Lancet Haematol.* **7**, e196.
10. Grimwade, D., et al. (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. *J. Clin. Oncol.* **27**, 3650.
11. Hochhaus, A., et al. (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia* **34**, 966.
12. Hochhaus, A., et al. (2017) Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **29(Suppl 4)**, iv261.
13. Hoelzer, D., et al. (2016) Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **27**, v69.
14. Klampfl, T., et al. (2013) Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. *N. Engl. J. Med.* **369**, 2379.
15. Kröger, N. (2007) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. *Blood* **109**, 1316.
16. Langabeer, S., et al. (2015) Molecular diagnostics of myeloproliferative neoplasms. *Eur. J. Haematol.* **95**, 270.
17. Leukemia and Lymphoma Society ALL Booklets: https://www.lls.org/sites/default/files/file_assets/PS33_AdultALL_2020.pdf and https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/PS37_Pediatric_ALL_1_21.pdf. Accessed March 22, 2021.
18. Leukemia and Lymphoma Society AML Booklet: https://www.lls.org/sites/default/files/file_assets/PS32_AML_Booklet_2019_FINAL.pdf. Accessed March 22, 2021.
19. Leukemia and Lymphoma Society CLL Booklet: https://www.lls.org/sites/default/files/file_assets/PS34_CLL_Booklet_2019_FINAL.pdf. Accessed March 22, 2021.
20. Leukemia and Lymphoma Society CML Booklet: https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/PS31_CMLBooklet_1_21.pdf. Accessed March 22, 2021.
21. Leukemia and Lymphoma Society: Facts. 2019–2020: https://www.lls.org/sites/default/files/file_assets/PS80%20Facts_Book_2019-20_FINAL.pdf
22. Leukemia and Lymphoma Society MPN Booklet: https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/MPNs_booklet_12_17_FINAL.pdf. Accessed March 22, 2021.
23. Quintas-Cardama, A., et al. (2013) Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α -2a. *Blood* **122**, 893.
24. Sanz, M.A., et al. (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. *Blood* **133**, 1630.
25. Titmarsh, G.J., et al. (2014) How common are myeloproliferative neoplasms? A systematic review and meta-analysis. *Am. J. Hematol.* **89**, 581.
26. Vannucchi, A.M. and Harrison, C.N. (2017) Emerging treatments for classical myeloproliferative neoplasms. *Blood* **129**, 693.
27. Vannucchi, A.M., et al. (2015) Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26 Suppl 5**, v85.
28. <http://seer.cancer.gov/statfacts/>. Accessed March 22, 2021.

Trademarks: Sample to Insight®, QIAGEN® (QIAGEN Group); Besremi® (Pharmaessenita Corporation); Bosulif® (Pfizer Inc.); Gleevec®, Jakavi®, Tasigna® (Novartis AG); Hydrea®, Sprycel® (Bristol-Myers Squibb Oncology); ICLUSIG® (ARIAD Pharmaceuticals, Inc.); Jakafi® (Incyte Corporation). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, may still be protected by law.

© 2021 QIAGEN, all rights reserved. PROM-6094-003